CODX - Co-Diagnostics, Inc. Common Stock logo

Co-Diagnostics, Inc. Common Stock

CODX

Co-Diagnostics develops and manufactures molecular diagnostic reagents for detecting nucleic acids. Its offerings include tests for infectious diseases like COVID-19, and tools for cancer screening and agricultural applications, serving both domestic and international markets.

⚕️ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 5 years ago →$2today

Score Overview

1 Year
Score
Net Growth-0.34%
Net TrendShrank
Net Income Consistency—
Rev Growth15.89%
Rev TrendGrew
Revenue Consistency—
5 Years
Score0.8
Net Growth-228.36%
Net TrendNever
Net Income Consistency—
Rev Growth-99.26%
Rev Trend20%
Revenue Consistency—
All Time
Score
Net Growth-4x
Net Trend33%
Net Income Consistency
Rev Growth94x
Rev Trend33%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Co-Diagnostics, Inc. Common Stock has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CODX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 0.57—
1 Year2025-10-22
$ 9.56-94.04%
5 Years2021-10-22
$ 250.50-99.77%
All Time2017-07-12
$ 174.30-99.67%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 721.39K-$ 47M$ 3M
2025$ 622.49K-$ 46M$ 11M
2024$ 3M-$ 37M$ 29M
2023$ 6M-$ 35M$ 58M
2022$ 34M-$ 14M$ 81M
2021$ 97M$ 36M$ 89M
2020$ 74M$ 42M$ 47M
2019-$ 6M$ 893.14K
2018-$ 6M$ 950.24K
IPO2017$ 7.66K-$ 6M$ 3M
CODX - Co-Diagnostics, Inc. Common Stock logo

Co-Diagnostics, Inc. Common Stock fundamental performance

Between 2020 and 2025, revenue declined from $ 74M to $ 622.49K and net income went from $ 42M to -$ 46M. Revenue increased in 1 of those 5 years; net income in 0.

Across Co-Diagnostics, Inc. Common Stock's full reported history, from 2017 to 2025, revenue grew from $ 7.66K to $ 622.49K and net income went from -$ 6M to -$ 46M. Revenue increased in 33% of the years measured; net income in 33%.

Co-Diagnostics, Inc. Common Stock currently holds a 5-year HDB Score of 0.8 out of 10. How the HDB Score is calculated.

Membership

Explore CODX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies